


Exhibits Referenced in Addendum Regarding  
Certain Summary Exhibits  
(Part 5)

# Substantial Sales of Schering's Proventil Were Priced Within 2% of WAC




Defendants' Exhibit

2956

01-12257 - PBS

# Substantial Sales of Schering's Proventil Were Priced Within 5% of WAC



Defendants' Exhibit

2957

01-12257 - PBS

Confidential

**Distribution of Sales  
by Percentage of WAC Paid by Schering Customers <sup>1</sup>**  
**Intron-A <sup>2</sup>**  
**1991 - 2004**

<u>Percentage of WAC <sup>3</sup></u>			
<u>Greater Than</u>	<u>Less Than or Equal To</u>	<u>Sales</u>	<u>Percent of Sales</u>
<u>(Percent)</u>		<u>(Dollars)</u>	<u>(Percent)</u>
(a)	(b)	(c)	(d)
100		\$ 255,654,934.57	12.10 %
99	100	370,317,472.93	17.52
98	99	747,876,047.92	35.38
97	98	198,441,552.79	9.39
96	97	57,162,167.54	2.70
95	96	28,316,567.21	1.34
90	95	117,387,791.56	5.55
85	90	157,163,598.68	7.44
80	85	69,015,010.87	3.27
	80	112,235,468.28	5.31

Notes: - Sales exclude non-sales transactions, and do not include rebates found in the rebates files. If sales dollars for a particular NDC and customer number for the whole year were negative, they were dropped.

<sup>1</sup> "ASP" is calculated by customer as identified by customer number.

<sup>2</sup> The NDCs used were all Schering Intron-A NDCs analyzed in the MDL (00085012002, 00085012003, 00085012004, 00085012005, 00085028502, 00085053901, 00085057102, 00085057106, 00085064703, 00085064704, 00085064705, 00085068901, 00085076901, 00085092301, 00085095301, 00085111001, 00085113301, 00085116801, 00085117901, 00085117902, 00085118401, 00085118402, 00085119101, 00085119102, 00085123501, 00085124201, 00085125401).

<sup>3</sup> WAC, which is calculated as AWP/1.2 until January 1, 2002 and AWP/1.25 thereafter, is measured at the June 30th value of AWP. In cases where a product's first reported AWP occurs after June 30th, the first reported AWP is used.

Sources: Schering Sales Data.

"Comprehensive Price History File," 2005 Wolters Kluwer Health (Medispan).

"Declaration of Raymond S. Hartman in Support of Plaintiffs' Claims of Liability and Calculation of Damages," December 15, 2005.


Defendants' Exhibit

2934

01-12257 - PBS



# Substantial Sales of Schering's Intron-A Were Priced Within 2% of WAC




Defendants' Exhibit

2958

01-12257 - PBS

# Substantial Sales of Schering's Intron-A Were Priced Within 5% of WAC



Defendants' Exhibit

2959

01-12257 - PBS

Confidential

**Distribution of Sales  
by Percentage of WAC Paid by Schering Customers <sup>1</sup>**  
**Temodar <sup>2</sup>**  
**1991 - 2004**

Percentage of WAC <sup>3</sup>		Sales (Dollars)	Percent of Sales (Percent)
Greater Than (Percent)	Less Than or Equal To		
(a)	(b)	(c)	(d)
100		\$ 18,463,636.01	3.30 %
99	100	194,085,289.02	34.68
98	99	219,063,580.96	39.14
97	98	82,298,391.45	14.71
96	97	2,561,554.51	0.46
95	96	12,544,999.97	2.24
90	95	2,775,307.98	0.50
85	90	4,934,451.28	0.88
80	85	4,176,721.99	0.75
	80	18,754,799.73	3.35

Notes: - Sales exclude non-sales transactions, and do not include rebates found in the rebates files. If sales dollars for a particular NDC and customer number for the whole year were negative, they were dropped.

<sup>1</sup> "ASP" is calculated by customer as identified by customer number.

<sup>2</sup> The NDCs used were all Schering Temodar NDCs analyzed in the MDL (00085124401, 00085124402, 00085124801, 00085124802, 00085125201, 00085125202, 00085125901, 00085125902).

<sup>3</sup> WAC, which is calculated as AWP/1.2 until January 1, 2002 and AWP/1.25 thereafter, is measured at the June 30th value of AWP. In cases where a product's first reported AWP occurs after June 30th, the first reported AWP is used.

Sources: Schering Sales Data.

"Comprehensive Price History File," 2005 Wolters Kluwer Health (Medispan).

"Declaration of Raymond S. Hartman in Support of Plaintiffs' Claims of Liability and Calculation of Damages," December 15, 2005.

Defendants' Exhibit

2935

01-12257 - PBS